WebCetuximab should be used with caution in patients with a history of keratitis, ulcerative keratitis or severe dry eye. Contact lens use is also a risk factor for keratitis and … WebFeb 13, 2024 · Patient Selection. Select patients with metastatic colorectal cancer (CRC) for treatment with ERBITUX based on the presence of: Ras wild-type, EGFR-expressing CRC [see Clinical Studies ()], or; BRAF V600E mutation-positive metastatic CRC [see Clinical Studies ()]; Information on FDA-approved tests for the detection of K-Ras or BRAF …
Cetuximab Uses, Side Effects & Warnings - Drugs.com
WebFDA approves new dosing regimen for cetuximab. On April 6, 2024, the Food and Drug Administration approved a new dosage regimen of 500 mg/ m2 as a 120-minute … WebNov 8, 2011 · The approval, which is based on data from the landmark EXTREME (ErbituX in first-line Treatment of REcurrent or MEtastatic head & neck cancer) trial, makes … offshore versus onshore wind
Success Story: Erbitux (NSC 632307) - dtp.cancer.gov
WebApproval was based on a randomized, active-controlled, open-label, multicenter trial (COLUMBUS; NCT01909453) in 577 patients with BRAF V600E or V600K mutation … WebJan 16, 2024 · tender, swollen glands in the neck. tightness in the chest. tingling of the hands or feet. trouble with breathing on exertion. trouble with swallowing. unusual bleeding or bruising. unusual tiredness or weakness. unusual weight gain or loss. voice changes. WebMay 8, 2024 · Cetuximab - StatPearls - NCBI Bookshelf. Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor with the following FDA-approved indications: … offshore valley